To view this email as a web page, go here.
Message below is a paid advertisement. Content is provided by the sponsor.
 
 
NexGard® (afoxolaner) provides powerful protection against fleas and ticks.
 
 
For years, NexGard® (afoxolaner) has been a trusted name in flea and tick control. Specially designed to provide the flea and tick protection that your patients deserve in a form that dogs will love, you can have confidence in every chew.

Want to make compliance with your flea/tick control recommendations easy? What could be easier than giving the flea and tick chew that is the #1 preferred by dogs?1 You can feel good about recommending NexGard; it's the chew that pet owners can enjoy giving, because their dogs are begging for it month after month.

And, it's the only flea/tick control product that combines all of the following benefits into an easy-to-give chew.
  • Effective when given with or without food
  • Safe and effective for puppies as young as 8 weeks and weighing 4 lbs or more
  • The only oral product approved to kill fleas and ticks that is available in just four sizes (SKUs)
  • The only product FDA-approved to prevent Lyme infections by killing infected Ixodes scapularis ticks
  • Easy monthly dosing -- 66% of dog owners say that it's easier to remember monthly dosing over dosing every 12 weeks2
 
LEARN MORE!
 
IMPORTANT SAFETY INFORMATION:
NexGard is for use in dogs only. The most frequently reported adverse reactions include vomiting, pruritus, lethargy, diarrhea and lack of appetite. The safe use of NexGard in pregnant, breeding, or lactating dogs has not been evaluated. Use with caution in dogs with a history of seizures or neurologic disorders. Click here for full prescribing information or visit www.NexGardClinic.com.
 
Premier logo
 
 
Boehringer Ingelheim Animal Health USA Inc.
 

1 Data on file
2 Data on file


NexGard® is a registered trademark of the Boehringer Ingelheim Group. ©2019 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0281-2019.

You are receiving this email because you opted-in to receive communications from Boehringer Ingelheim Animal Health USA Inc.